Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Elanco expects Befrena to launch in the US in the first half of 2026
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D
Roche says its new assay “resolves this challenge by delivering accurate and specific results
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
